EUVIMEDEUVIMED entdecken
Open Access

Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC

Lova Sun, Roger B Cohen, Christopher A D'Avella, Aditi P Singh, Jonathan D Schoenfeld, Glenn J Hanna

JAMA Network Open · 19.08.2024 · 7 (8) · e2428526

DOI: 10.1001/jamanetworkopen.2024.28526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 19.08.2024. Verfasst von Lova Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Head and Neck Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Immune checkpoint inhibition (ICI) is a frontline treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but questions remain surrounding optimal duration of therapy, benefits and risks of ICI rechallenge, and efficacy in first vs subsequent lines of therapy.

Objectives

To estimate survival in US patients receiving ICI-based treatment for R/M HNSCC, compare outcomes associated with treatment discontinuation vs continuation at 1 or 2 years, and assess outcomes after immunotherapy rechallenge. Design, Setting, and Participants This retrospective, population-based cohort study included adult patients in the Flatiron Health nationwide oncology database treated with immunotherapy for R/M HNSCC from 2015 to 2023. Data cutoff was August 31, 2023; data analysis was conducted from December 2023 to February 2024. Exposures Treatment continuation vs discontinuation at 1 and 2 years; rechallenge with ICI after at least a 60-day period off ICI therapy without intervening systemic treatment (immediate rechallenge), or with intervening systemic treatment (delayed rechallenge). Main Outcomes and Measures Overall survival (OS) from ICI initiation was analyzed using the Kaplan-Meier method. Cox multivariable regression was used to examine associations of key variables (line of therapy, human papillomavirus [HPV] status, Eastern Cooperative Oncology Group [ECOG] performance status) with survival.

Results

The cohort included 4549 patients with R/M HNSCC who received ICI-containing therapy (median [IQR] age, 66 [59-72] years; 3551 [78.1%] male; 56 [1.2%] Asian, 260 [5.7%] Black or African American, 3020 [66.4%] White, 1213 [26.7%] other or unknown race; 3226 [70.9%] ECOG performance status 0 or 1). There were 3000 patients (65.9%) who received ICI in frontline and 1207 (26.5%) in second line; 3478 patients (76.5%) received ICI monotherapy. Median (IQR) OS was 10.9 (4.1-29.1) months and was longer in patients who received ICI in frontline therapy (12.2 [4.8-32.0] vs 8.7 [3.2-22.4] months), had HPV-positive cancer (16.6 [6.5-43.9] vs 8.8 [3.5-24.0] months), and had ECOG performance status 0 or 1 (13.5 [5.2-33.9] vs 5.5 [2.0-13.7] months). There were no survival differences on adjusted analysis between patients who stopped vs those who continued ICI at 1 or 2 years. Median (IQR) OS after ICI rechallenge was 15.7 (13.7-21.9) months in the immediate rechallenge group and 9.9 (3.7-18.1) months in the delayed rechallenge group. Conclusions and Relevance In this large cohort study of patients with R/M HNSCC receiving ICI-based therapy, survival estimates closely mirrored clinical trial results, both in frontline and later-line settings. Discontinuation of ICI in long-term responders at 1 or 2 years may be a reasonable strategy that does not appear to compromise survival. ICI rechallenge was associated with clinical benefit in a subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedDuration of TherapyTreatment OutcomeUnited StatesAdultCohort Studies

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Hematology Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Dana Farber Cancer Institute, Boston, Massachusetts.
  • Brigham and Women's Hospital, Boston, Massachusetts.

Zitieren

APA

Sun, L., Cohen, R. B., D'Avella, C. A., Singh, A. P., Schoenfeld, J. D., & Hanna, G. J. (2024). Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC. JAMA Network Open, 7(8), e2428526. https://doi.org/10.1001/jamanetworkopen.2024.28526

Vancouver

Sun L, Cohen RB, D'Avella CA, Singh AP, Schoenfeld JD, Hanna GJ. Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC. JAMA Network Open. 2024;7(8):e2428526. doi:10.1001/jamanetworkopen.2024.28526

BibTeX
@article{Sun2024,
  author = {Sun, Lova and Cohen, Roger B and D'Avella, Christopher A and Singh, Aditi P and Schoenfeld, Jonathan D and Hanna, Glenn J},
  title = {Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {8},
  pages = {e2428526},
  doi = {10.1001/jamanetworkopen.2024.28526}
}
Kostenlos starten →